| Literature DB >> 16290270 |
Joseph Rogers1, Rena Li, Diego Mastroeni, Andrew Grover, Brian Leonard, Geoffrey Ahern, Phillip Cao, Heather Kolody, Linda Vedders, William P Kolb, Marwan Sabbagh.
Abstract
Brain deposits of amyloid beta peptide (Abeta) have been a diagnostic hallmark of Alzheimer's disease (AD) for nearly a century. Recent studies have demonstrated that Abeta is also present in peripheral blood. Here, we present evidence that circulating Abeta42 is subject to complement C3b-dependent adherence to complement receptor 1 (CR1) on erythrocytes, a classical set of mechanisms by which pathogens and proteins recognized as foreign are cleared from the bloodstream. Levels of Abeta42 targeted by this pathway differ significantly in AD compared to mild cognitive impairment and nondemented elderly controls.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16290270 DOI: 10.1016/j.neurobiolaging.2005.09.043
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673